In cell lines directly generated from patients with anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancers that were resistant to second-generation ALK inhibitors, multiple different bypass resistance mutations ultimately converged on the same signaling mode to increase cell growth.